Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra revenue up 11.5% in Q4 2024; full-year GAAP loss of $0.09 per share, 2025 EPS guided lower

Mixed Impact 4 of 5 earnings Written later

Integra LifeSciences reported fourth-quarter 2024 revenue of $442.6 million, up 11.5% on a reported basis but up 3.5% on an organic basis, and adjusted earnings of $0.97 per diluted share versus $0.89. For full-year 2024 it posted a GAAP net loss of $6.9 million, or $(0.09) per diluted share, and adjusted earnings per share fell to $2.56 from $3.10, with 2025 adjusted EPS guided to $2.41 to $2.51.

Key points

  • Q4 2024 revenue $442.6 million, up 11.5% reported and 3.5% organic; GAAP EPS $0.25 in both Q4 2024 and Q4 2023
  • Full-year 2024 GAAP net loss $6.9 million, or $(0.09) per diluted share, versus GAAP net income of $67.7 million, or $0.84, in 2023
  • Full-year 2024 adjusted EBITDA $322.2 million, down $47.4 million; 2025 revenue guidance $1,650 million to $1,715 million
  • Q1 2025 adjusted EPS guidance $0.40 to $0.45; full-year 2025 adjusted EPS guidance $2.41 to $2.51

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECFeb 25, 2025, 6:15 AM ET
Accession number0000917520-25-000014

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.